Zacks Research Predicts Atossa Genetics FY2027 Earnings

Atossa Genetics Inc. (NASDAQ:ATOS) – Equities researchers at Zacks Research issued their FY2027 EPS estimates for shares of Atossa Genetics in a research note issued to investors on Wednesday, May 13th. Zacks Research analyst D. Bautz forecasts that the company will post earnings of ($3.59) per share for the year. The consensus estimate for Atossa Genetics’ current full-year earnings is ($4.52) per share.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12).

A number of other brokerages have also commented on ATOS. HC Wainwright boosted their price target on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Weiss Ratings lowered shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Finally, Ascendiant Capital Markets decreased their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $36.33.

Atossa Genetics Price Performance

Atossa Genetics stock opened at $5.16 on Thursday. Atossa Genetics has a 12-month low of $3.76 and a 12-month high of $19.35. The firm’s fifty day moving average is $5.26 and its 200 day moving average is $8.03. The company has a market capitalization of $44.43 million, a PE ratio of -1.61 and a beta of 1.25.

Institutional Trading of Atossa Genetics

Several institutional investors have recently made changes to their positions in ATOS. Bank of America Corp DE grew its stake in shares of Atossa Genetics by 51.3% in the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock worth $105,000 after acquiring an additional 37,809 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in shares of Atossa Genetics by 357.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after acquiring an additional 325,340 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Atossa Genetics in the 2nd quarter worth $381,000. Ameriprise Financial Inc. bought a new stake in shares of Atossa Genetics in the 2nd quarter worth $2,468,000. Finally, Hudson Bay Capital Management LP bought a new stake in shares of Atossa Genetics in the 2nd quarter worth $26,000. Institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.